DVL1 and non-small cell lung carcinoma: Kaplan-Meier analysis suggested a notably lower survival period for patients with NSCLC with positive Dvl1 expression than for patients with negative Dvl1 expression (74.486 ± 5.000 vs 46.334 ± 4.085 months, P < 0.05; Figure 2A).